Novo Nordisk A/S - share repurchase programme
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
Novo Nordisk: Q4 Earnings Snapshot
Novo Nordisk A/S (NVO) on Wednesday reported fourth-quarter earnings of $4.04 billion. The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall ...
Nasdaq6d
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC ...
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members ...
NVO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
The Local6d
Danish weight-loss drugmaker Novo Nordisk posts huge profit jump
Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on ...
Inc9d
Novo Nordisk Foundation Will Not Fill Funding Gaps
LONDON (Reuters) – The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a ...
NVO CLASS ACTION UPDATE: Novo Nordisk Investors are Reminded to Contact BFA Law before Imminent March 25 Deadline
Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...
Novo Nordisk A/S: Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
At the Annual General Meeting on 27 March 2025, the Board of Directors will propose a final dividend of DKK 7.90 for 2024 per share. The expected total dividend for 2024 will increase 21% to DKK 11.40 ...
Reuters7d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...